CyanVac eyes fundraise for parainfluenza-vectored Covid-19 vaccine after December data
CyanVac’s CVXGA1 is a nasally administered Covid-19 vaccine that uses a parainfluenza virus 5 vector.
Clinical Research
Africa has seen the largest growth in central nervous system related trials over the past decade
We've analysed 10 years' worth of clinical trials data from GlobalData to pick out key...
ICON Q&A: talking affordability in cell and gene therapies
ICON’s Tamie Joeckel discusses the challenges of making cell and gene therapies affordable for payers...
The reality of optimising real-world data
Researchers and pharma companies must harness the potential of real-world data to optimise rare disease...
Unmet needs and opportunities for axillary hyperhidrosis
Current unmet needs in the axillary hyperhidrosis (AH) therapeutics market create opportunities for companies to...
Living medicines: using bacteria to fight cancer
As well as playing a role in cancer growth and chemo resistance, bacteria have shown great promise in treating cancer directly.
Oral Covid-19 drugs: Merck’s molnupiravir and its closest rivals
With Merck and Ridgeback revealing their topline Phase III data, the stage is set for fellow frontrunners Pfizer, Roche and Atea.
Merck and Ridgeback’s molnupiravir rollout difficult to map in uncertain Covid-19 landscape
Questions about oral molnupiravir's deployment still loom large as clinicians await crucial late-stage trial results.
Novavax Covid-19 vaccine booster: safety and manufacturing questions remain
Novavax’s Covid-19 vaccine could find its niche as a booster shot, but questions linger around its safety and production.
